Drugs / PF-05230907
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02687191 | Nov 2016 → Jan 2018 | intracerebral hemorrhage | Pfizer | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02537002 | Sep 2015 → Mar 2016 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01897142 | Sep 2013 → Mar 2015 | — | Pfizer | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-05230907 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02537002 ↗ |
| Known as | Fxa variant i16l | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650415 ↗ |
| Route | Intravenous | “IV bolus” NCT01897142 ↗ |